{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:52:42Z","timestamp":1791132762791,"version":"4.1.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Substance-use disorders are major accelerators of cardiometabolic disease, yet this dimension remains insufficiently recognized within addiction care. Individuals with substance-use disorders frequently exhibit hypertension, adverse lipid profiles, visceral adiposity, metabolic syndrome, chronic low-grade inflammation and autonomic imbalance, contributing to markedly elevated cardiovascular morbidity and premature mortality. The recent European Society of Cardiology Clinical Consensus Statement on mental health and cardiovascular disease highlights this gap and calls for structured cardiometabolic assessment and prevention strategies within behavioural and psychiatric population. Glucagon-like peptide-1 receptor therapies have emerged as multisystem agents relevant to both addictive behaviour and cardiometabolic health. Experimental and early clinical evidence demonstrates reductions in craving, improved reward regulation and attenuation of impulsive consumption across alcohol, nicotine, stimulant use and binge-type eating, mediated through gut\u2013brain communication, mesolimbic dopamine circuitry, hypothalamic pathways and stress-responsive networks. In parallel, these therapies induce clinically meaningful reductions in body weight, visceral adiposity, blood pressure and inflammatory burden, while improving glucose regulation and cardiometabolic markers. Large cardiovascular outcome trials demonstrate reductions in major adverse cardiovascular events in high-risk populations, and emerging primary-prevention analyses report favourable changes in estimated cardiovascular risk even without established cardiovascular disease. This review integrates biological, clinical and real-world evidence to propose a unified neurocardiometabolic framework in which glucagon-like peptide-1 receptor therapies may simultaneously influence addictive behaviour and long-term cardiovascular risk trajectories. We outline mechanistic foundations and potential clinical applications within detoxification programmes, relapse-prevention settings, dual-diagnosis services and addiction care, while highlighting the need for further clinical validation before routine implementation.<\/jats:p>","DOI":"10.1093\/ehjopen\/oeag101","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:26:40Z","timestamp":1781612800000},"source":"Crossref","is-referenced-by-count":1,"title":["Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5625-2771","authenticated-orcid":false,"given":"Jose","family":"Seijas-Amigo","sequence":"first","affiliation":[{"name":"Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela , Traves\u00eda da Choupana s\/n, Santiago de Compostela 15706 ,","place":["Spain"]},{"name":"Fundaci\u00f3n Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (FIDIS) , Santiago de Compostela 15706 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid 28029 ,","place":["Spain"]},{"name":"University of Santiago de Compostela, Santiago de Compostela 15782 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Salgado-Barreira","sequence":"additional","affiliation":[{"name":"University of Santiago de Compostela, Santiago de Compostela 15782 ,","place":["Spain"]},{"name":"Department of Preventive Medicine and Public Health, University of Santiago de Compostela , Santiago de Compostela 15782 ,","place":["Spain"]},{"name":"Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiolog\u00eda y Salud P\u00fablica CIBERESP), Carlos III Health Institute , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Eiras","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV) , Madrid 28029 ,","place":["Spain"]},{"name":"Traslational Cardiology Group, Health Research Institute , Santiago de Compostela 15706, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Arias-Rivas","sequence":"additional","affiliation":[{"name":"Neurology Department, Complejo Hospitalario Universidad de Santiago de Compostela , Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rodriguez-Carnero","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Complejo Hospitalario Universidad de Santiago de Compostela , Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Rodriguez-Ma\u00f1ero","sequence":"additional","affiliation":[{"name":"Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela , Traves\u00eda da Choupana s\/n, Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ramon","family":"Gonzalez-Juanatey","sequence":"additional","affiliation":[{"name":"Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela , Traves\u00eda da Choupana s\/n, Santiago de Compostela 15706 ,","place":["Spain"]},{"name":"Fundaci\u00f3n Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (FIDIS) , Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026070305010569300_oeag101-B1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"key":"2026070305010569300_oeag101-B2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"2026070305010569300_oeag101-B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/B978-0-12-801284-0.00010-5","article-title":"Neuroimmune basis of alcoholic brain damage","volume":"118","author":"Crews","year":"2014","journal-title":"Int Rev Neurobiol"},{"key":"2026070305010569300_oeag101-B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1196\/annals.1441.030","article-title":"Chronic stress, drug use, and vulnerability to addiction","volume":"1141","author":"Sinha","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"2026070305010569300_oeag101-B5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10826084.2018.1508297","article-title":"Psychological and autonomic correlates of emotion dysregulation among women in substance use disorder treatment","volume":"54","author":"Price","year":"2019","journal-title":"Subst Use Misuse"},{"key":"2026070305010569300_oeag101-B6","doi-asserted-by":"crossref","DOI":"10.3390\/nu15040958","article-title":"Alcohol intake and arterial hypertension: retelling of a multifaceted story","volume":"15","author":"Vacca","year":"2023","journal-title":"Nutrients"},{"key":"2026070305010569300_oeag101-B7","doi-asserted-by":"crossref","DOI":"10.1080\/20008066.2025.2478792","article-title":"Systemic inflammation and metabolic syndrome components in threshold\/subthreshold posttraumatic stress disorder and food addiction in a Polish community sample","volume":"16","author":"Stojek","year":"2025","journal-title":"Eur J Psychotraumatol"},{"key":"2026070305010569300_oeag101-B8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12916-014-0182-6","article-title":"Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers","volume":"12","author":"Roerecke","year":"2014","journal-title":"BMC Med"},{"key":"2026070305010569300_oeag101-B9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/add.13897","article-title":"Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study","volume":"112","author":"Darke","year":"2017","journal-title":"Addiction"},{"key":"2026070305010569300_oeag101-B10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/COH.0000000000000407","article-title":"Tobacco, illicit drugs use and risk of cardiovascular disease in patients living with HIV","volume":"12","author":"Raposeiras-Roub\u00edn","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2026070305010569300_oeag101-B11","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1093\/eurheartj\/ehaf191","article-title":"2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee","volume":"46","author":"Bueno","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070305010569300_oeag101-B12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"2026070305010569300_oeag101-B13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026070305010569300_oeag101-B14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"key":"2026070305010569300_oeag101-B15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol Behav"},{"key":"2026070305010569300_oeag101-B16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026070305010569300_oeag101-B17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B18","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2026070305010569300_oeag101-B20","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2026070305010569300_oeag101-B26","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026070305010569300_oeag101-B28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B29","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108681","article-title":"Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: a 24 months follow-up study","volume":"173","author":"D'Onofrio","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026070305010569300_oeag101-B30","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"2026070305010569300_oeag101-B31","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1111\/dom.15226","article-title":"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026070305010569300_oeag101-B32","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103312","article-title":"Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: a 44-week open label prospective study","volume":"19","author":"Seijas-Amigo","year":"2025","journal-title":"Diabetes Metab Syndr"},{"key":"2026070305010569300_oeag101-B33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.35946\/arcr.v38.2.06","article-title":"Alcohol's effects on the cardiovascular system","volume":"38","author":"Piano","year":"2017","journal-title":"Alcohol Res"},{"key":"2026070305010569300_oeag101-B34","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1136\/heartjnl-2023-322520","article-title":"Prevalence and impact of recreational drug use in patients with acute cardiovascular events","volume":"109","author":"Pezel","year":"2023","journal-title":"Heart"},{"key":"2026070305010569300_oeag101-B35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"2026070305010569300_oeag101-B36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiol Behav"},{"key":"2026070305010569300_oeag101-B37","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/npp.2014.74","article-title":"Glucagon-like Peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed","volume":"39","author":"Alhadeff","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"2026070305010569300_oeag101-B38","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"key":"2026070305010569300_oeag101-B39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"2026070305010569300_oeag101-B40","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"2026070305010569300_oeag101-B41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict Biol"},{"key":"2026070305010569300_oeag101-B42","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.clnu.2024.05.035","article-title":"Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist","volume":"43","author":"Elfers","year":"2024","journal-title":"Clin Nutr"},{"key":"2026070305010569300_oeag101-B43","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"2026070305010569300_oeag101-B44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/mp.2017.91","article-title":"A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling","volume":"23","author":"Hsu","year":"2018","journal-title":"Mol Psychiatry"},{"key":"2026070305010569300_oeag101-B45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20 Suppl 1","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026070305010569300_oeag101-B46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"2026070305010569300_oeag101-B47","article-title":"Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection","volume":"12","author":"Battistoni","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026070305010569300_oeag101-B48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026070305010569300_oeag101-B49","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.2007.05030503","article-title":"Stress, dysregulation of drug reward pathways, and the transition to drug dependence","volume":"164","author":"Koob","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2026070305010569300_oeag101-B50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.neubiorev.2019.09.007","article-title":"A potential role for microglia in stress- and drug-induced plasticity in the nucleus accumbens: a mechanism for stress-induced vulnerability to substance use disorder","volume":"107","author":"McGrath","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"2026070305010569300_oeag101-B51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864858","article-title":"Dysregulated hypothalamic-pituitary-adrenal axis is associated with increased inflammation and worse outcomes after ischemic stroke in diabetic mice","volume":"13","author":"Kim","year":"2022","journal-title":"Front Immunol"},{"key":"2026070305010569300_oeag101-B52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.tem.2023.02.005","article-title":"Neuroendocrine regulation in stroke","volume":"34","author":"Datta","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"2026070305010569300_oeag101-B53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.biopsych.2012.12.020","article-title":"The addictive dimensionality of obesity","volume":"73","author":"Volkow","year":"2013","journal-title":"Biol Psychiatry"},{"key":"2026070305010569300_oeag101-B54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1369-1600.2010.00308.x","article-title":"Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving","volume":"17","author":"Leggio","year":"2012","journal-title":"Addict Biol"},{"key":"2026070305010569300_oeag101-B55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.psyneuen.2012.10.021","article-title":"Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake","volume":"38","author":"Monteleone","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"2026070305010569300_oeag101-B56","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.celrep.2020.01.045","article-title":"Blunted vagal cocaine- and amphetamine-regulated transcript promotes hyperphagia and weight gain","volume":"30","author":"Lee","year":"2020","journal-title":"Cell Rep"},{"key":"2026070305010569300_oeag101-B57","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70004","article-title":"Effects of GLP-1 receptor agonists in alcohol use disorder","volume":"136","author":"Klausen","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2026070305010569300_oeag101-B58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 Analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026070305010569300_oeag101-B59","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"2026070305010569300_oeag101-B60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44385-025-00036-8","article-title":"Central and peripheral neural circuits regulating glucose homeostasis","volume":"2","author":"Espinoza","year":"2025","journal-title":"NPJ Biomed Innov"},{"key":"2026070305010569300_oeag101-B61","doi-asserted-by":"crossref","DOI":"10.3390\/nu13124426","article-title":"Transdiagnostic perspective of impulsivity and compulsivity in obesity: from cognitive profile to self-reported dimensions in clinical samples with and without diabetes","volume":"13","author":"Testa","year":"2021","journal-title":"Nutrients"},{"key":"2026070305010569300_oeag101-B62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110318","article-title":"Impulsivity and compulsivity in binge eating disorder: a systematic review of behavioral studies","volume":"110","author":"Carr","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2026070305010569300_oeag101-B63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes Rev"},{"key":"2026070305010569300_oeag101-B64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40519-025-01720-9","article-title":"The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis","volume":"30","author":"Radkhah","year":"2025","journal-title":"Eat Weight Disord"},{"key":"2026070305010569300_oeag101-B65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/qjmed\/hcae095","article-title":"Starting GLP-1 therapy may induce impulse control disorders","volume":"117","author":"Playford","year":"2024","journal-title":"QJM"},{"key":"2026070305010569300_oeag101-B66","article-title":"Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026070305010569300_oeag101-B67","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jinf.2008.03.003","article-title":"Clinical implications of addiction related immunosuppression","volume":"56","author":"Reece","year":"2008","journal-title":"J Infect"},{"key":"2026070305010569300_oeag101-B68","doi-asserted-by":"crossref","first-page":"778","DOI":"10.14336\/AD.2022.0912","article-title":"\u03b4-opioid receptor, microglia and neuroinflammation","volume":"14","author":"Xu","year":"2023","journal-title":"Aging Dis"},{"key":"2026070305010569300_oeag101-B69","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hup.1251","article-title":"Immune system inflammation in cocaine dependent individuals: implications for medications development","volume":"27","author":"Fox","year":"2012","journal-title":"Hum Psychopharmacol"},{"key":"2026070305010569300_oeag101-B70","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrcardio.2015.91","article-title":"Cardiovascular risks and benefits of moderate and heavy alcohol consumption","volume":"12","author":"Fern\u00e1ndez-Sol\u00e0","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2026070305010569300_oeag101-B71","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2017.03.019","article-title":"Vascular disease in cocaine addiction","volume":"262","author":"Bachi","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026070305010569300_oeag101-B72","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0735-1097(97)00079-X","article-title":"Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy","volume":"29","author":"Benowitz","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026070305010569300_oeag101-B73","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026070305010569300_oeag101-B74","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Med Sci (Basel)"},{"key":"2026070305010569300_oeag101-B75","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026070305010569300_oeag101-B76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can J Physiol Pharmacol"},{"key":"2026070305010569300_oeag101-B77","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"2026070305010569300_oeag101-B78","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113113","article-title":"Neurotrophic and neuroprotective effects of a monomeric GLP-1\/GIP\/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury","volume":"324","author":"Li","year":"2020","journal-title":"Exp Neurol"},{"key":"2026070305010569300_oeag101-B79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes Metab Syndr"},{"key":"2026070305010569300_oeag101-B80","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obes Pillars"},{"key":"2026070305010569300_oeag101-B81","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"2026070305010569300_oeag101-B82","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","article-title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial","volume":"407","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"2026070305010569300_oeag101-B83","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","article-title":"Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes","volume":"24","author":"Wharton","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026070305010569300_oeag101-B84","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00592-025-02606-z","article-title":"GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes","volume":"63","author":"Gitto","year":"2025","journal-title":"Acta Diabetol"},{"key":"2026070305010569300_oeag101-B85","article-title":"Semaglutide in heart failure with preserved ejection fraction: emerging evidence and clinical implications","volume":"17","author":"Arty","year":"2025","journal-title":"Cureus"},{"key":"2026070305010569300_oeag101-B86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ahj.2015.07.014","article-title":"Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"170","author":"Chen","year":"2015","journal-title":"Am Heart J"},{"key":"2026070305010569300_oeag101-B87","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.jacep.2024.07.004","article-title":"Glucagon-like peptide-1 receptor agonists and atrial fibrillation recurrence after ablation: a fire without the smoke?","volume":"10","author":"Karakasis","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"2026070305010569300_oeag101-B88","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMra020617","article-title":"Management of drug and alcohol withdrawal","volume":"348","author":"Kosten","year":"2003","journal-title":"N Engl J Med"},{"key":"2026070305010569300_oeag101-B89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA"},{"key":"2026070305010569300_oeag101-B90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cvr\/cvq271","article-title":"GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons","volume":"89","author":"Griffioen","year":"2011","journal-title":"Cardiovasc Res"},{"key":"2026070305010569300_oeag101-B91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Invest"},{"key":"2026070305010569300_oeag101-B92","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0447.2009.01498.x","article-title":"Impact of substance use on the physical health of patients with bipolar disorder","volume":"121","author":"Garcia-Portilla","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"2026070305010569300_oeag101-B93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"DE Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"2026070305010569300_oeag101-B94","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/wps.20069","article-title":"A meta-analysis of cardio-metabolic abnormalities in drug na\u00efve, first-episode and multi-episode patients with schizophrenia versus general population controls","volume":"12","author":"Vancampfort","year":"2013","journal-title":"World Psychiatry"},{"key":"2026070305010569300_oeag101-B95","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2026070305010569300_oeag101-B96","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026070305010569300_oeag101-B97","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"2026070305010569300_oeag101-B98","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pcd.2023.05.004","article-title":"Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: a non-randomized multicenter study from the titration phase","volume":"17","author":"Seijas-Amigo","year":"2023","journal-title":"Prim Care Diabetes"},{"key":"2026070305010569300_oeag101-B99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wps.20128","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatry"},{"key":"2026070305010569300_oeag101-B100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2026070305010569300_oeag101-B101","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"key":"2026070305010569300_oeag101-B102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"2026070305010569300_oeag101-B103","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am J Psychiatry"},{"key":"2026070305010569300_oeag101-B104","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/oby.22653","article-title":"Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology","volume":"27","author":"Chao","year":"2019","journal-title":"Obesity (Silver Spring)"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/4\/oeag101\/68670185\/oeag101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/4\/oeag101\/68670185\/oeag101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:01:39Z","timestamp":1783069299000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeag101\/8723210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeag101","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"oeag101"}}